JP2007509141A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509141A5
JP2007509141A5 JP2006536485A JP2006536485A JP2007509141A5 JP 2007509141 A5 JP2007509141 A5 JP 2007509141A5 JP 2006536485 A JP2006536485 A JP 2006536485A JP 2006536485 A JP2006536485 A JP 2006536485A JP 2007509141 A5 JP2007509141 A5 JP 2007509141A5
Authority
JP
Japan
Prior art keywords
diazaspiro
isobutoxybenzyl
undecane
decane
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006536485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509141A (ja
Filing date
Publication date
Priority claimed from SE0302811A external-priority patent/SE0302811D0/xx
Application filed filed Critical
Publication of JP2007509141A publication Critical patent/JP2007509141A/ja
Publication of JP2007509141A5 publication Critical patent/JP2007509141A5/ja
Pending legal-status Critical Current

Links

JP2006536485A 2003-10-23 2004-10-21 新規ジアザスピロアルカンおよびccr8介在疾患処置のためのその使用 Pending JP2007509141A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0302811A SE0302811D0 (sv) 2003-10-23 2003-10-23 Novel compounds
PCT/SE2004/001522 WO2005040167A1 (en) 2003-10-23 2004-10-21 Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases

Publications (2)

Publication Number Publication Date
JP2007509141A JP2007509141A (ja) 2007-04-12
JP2007509141A5 true JP2007509141A5 (enExample) 2007-12-06

Family

ID=29546627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006536485A Pending JP2007509141A (ja) 2003-10-23 2004-10-21 新規ジアザスピロアルカンおよびccr8介在疾患処置のためのその使用

Country Status (17)

Country Link
US (1) US20070249648A1 (enExample)
EP (1) EP1678178A1 (enExample)
JP (1) JP2007509141A (enExample)
KR (1) KR20060088557A (enExample)
CN (1) CN1898239A (enExample)
AR (1) AR046600A1 (enExample)
AU (1) AU2004284028B2 (enExample)
BR (1) BRPI0415613A (enExample)
CA (1) CA2542226A1 (enExample)
IL (1) IL174698A0 (enExample)
MX (1) MXPA06004300A (enExample)
NO (1) NO20062335L (enExample)
SE (1) SE0302811D0 (enExample)
TW (1) TW200528451A (enExample)
UY (1) UY28572A1 (enExample)
WO (1) WO2005040167A1 (enExample)
ZA (1) ZA200603174B (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202133D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
SE0303090D0 (sv) * 2003-11-20 2003-11-20 Astrazeneca Ab Novel compounds
SE0303541D0 (sv) 2003-12-22 2003-12-22 Astrazeneca Ab New compounds
US7435830B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
WO2006107252A1 (en) * 2005-04-04 2006-10-12 Astrazeneca Ab Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
EP1869045A1 (en) * 2005-04-04 2007-12-26 AstraZeneca AB Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
JP2008534678A (ja) * 2005-04-04 2008-08-28 アストラゼネカ・アクチエボラーグ 新規ジアザスピロアルカン類およびccr8介在疾患の処置のためのそれらの使用
GB0514018D0 (en) * 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
TW200800999A (en) * 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
CA2669736C (en) 2005-11-03 2017-02-21 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
AU2007256597A1 (en) * 2006-06-09 2007-12-13 Icos Corporation Substituted phenyl acetic acids as DP-2 antagonists
CA2657639A1 (en) * 2006-07-19 2008-01-24 Astrazeneca Ab Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
CN101541805A (zh) 2006-09-15 2009-09-23 先灵公司 用于治疗疼痛和脂代射紊乱的氮杂环丁烷和氮杂环丁酮衍生物
MX2009002920A (es) * 2006-09-15 2009-04-01 Schering Corp Tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos.
CA2663500A1 (en) 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
WO2008099165A1 (en) * 2007-02-15 2008-08-21 Astrazeneca Ab Piperidine derivatives and their use for treatment of ccr8 mediated diseases
US8278313B2 (en) 2008-03-11 2012-10-02 Abbott Laboratories Macrocyclic spiro pyrimidine derivatives
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US20120083476A1 (en) * 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
WO2010151815A2 (en) * 2009-06-25 2010-12-29 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
DK2547679T3 (en) * 2010-03-19 2016-01-11 Pfizer 2,3 dihydro-1H-inden-1-yl-2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of ghrelin receptor
EP2773351B1 (en) 2011-10-31 2017-08-23 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
GB201122113D0 (en) * 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
WO2013184202A1 (en) * 2012-06-08 2013-12-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Fbxo3 inhibitors
CN104364239B (zh) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
MX368615B (es) 2012-09-25 2019-10-09 Hoffmann La Roche Derivados bicíclicos como inhibidores de la autotaxina (atx) que son inhibidores de la producción de ácido lisofosfatídico (lpa) y el uso de los mismos.
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
WO2015048570A2 (en) * 2013-09-26 2015-04-02 Sanford-Burnham Medical Research Institute Ebi2 modulators
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
DK3074400T3 (en) 2013-11-26 2018-01-15 Hoffmann La Roche Octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrole derivatives as autotaxin inhibitors
WO2015140130A1 (en) * 2014-03-17 2015-09-24 Remynd Nv Oxadiazole compounds
CA2937616A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
EA032357B1 (ru) 2014-03-26 2019-05-31 Ф. Хоффманн-Ля Рош Аг Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
ES2898765T3 (es) 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
UA121775C2 (uk) 2015-07-31 2020-07-27 Пфайзер Інк. 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl
CA2992889A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
WO2017050732A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
JP6876685B2 (ja) 2015-09-24 2021-05-26 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Atx阻害剤としての二環式化合物
BR112017026682A2 (pt) 2015-09-24 2018-08-14 Hoffmann La Roche novos compostos bicíclicos como inibidores de dupla ação de atx/ca
AU2016328436B2 (en) 2015-09-24 2020-05-14 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
KR20180081596A (ko) 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
EP3571191A1 (en) 2017-01-20 2019-11-27 Pfizer Inc 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
EP3571202B1 (en) 2017-01-23 2021-06-30 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ-ヘテロ二環式化合物およびその使用方法
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ.ホフマン-ラ ロシュ アーゲー Atxインヒビターとしての新規二環式化合物
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
CN110156674A (zh) * 2018-02-13 2019-08-23 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
MX2021000887A (es) 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
WO2020048829A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 3,9-diazaspiro[5.5]undecane compounds
CN113207291A (zh) * 2018-10-24 2021-08-03 亚瑞克西斯制药公司 2-(2-丙烯酰基-2,6-二氮杂螺[3.4]辛-6-基)-6-(1h-吲唑-4-基)苄腈衍生物及相关化合物作为用于抑制肿瘤转移的g12c突变kras蛋白的抑制剂
KR102885432B1 (ko) 2020-07-03 2025-11-14 난징 이뮤노파지 바이오테크 코., 엘티디. CCR8 억제제로 Tregs를 표적화하는 방법 및 조성물
BR112023015210A2 (pt) 2021-01-29 2023-11-07 Cedilla Therapeutics Inc Inibidores de cdk2 e métodos de uso dos mesmos
TW202309006A (zh) * 2021-04-30 2023-03-01 西班牙商塔拉森斯調節公司 作為sigma配體的新穎吡啶磺醯胺衍生物、其製備方法及用途,以及包含該吡啶-磺醯胺衍生物的醫藥組成物
CA3225439A1 (en) 2021-06-26 2022-12-29 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
EP4415706A4 (en) * 2021-10-13 2025-08-27 Vanqua Bio Inc SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND THEIR USES
TW202430180A (zh) 2022-11-30 2024-08-01 瑞士商愛杜西亞製藥有限公司 作為ccr8調節劑之芳基-及雜芳基-磺醯胺衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4010201A (en) * 1974-04-12 1977-03-01 The Upjohn Company Organic compounds
US4263317A (en) * 1979-09-06 1981-04-21 Hoechst-Roussel Pharmaceuticals, Inc. Spiro[cyclohexane-1,1'(3'H)-isobenzofuran]s
HRP20000495B1 (en) * 1998-02-04 2005-12-31 Banyu Pharmaceutical Co. N-acyl cyclic amine derivatives
WO2003037271A2 (en) * 2001-10-30 2003-05-08 Millennium Pharmaceuticals,Inc. Compounds, pharmaceutical compositions and methods of use therefor
SE0202133D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
AU2003261415C1 (en) * 2002-08-09 2010-01-14 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
US20070021498A1 (en) * 2004-10-14 2007-01-25 Nafizal Hossain Novel tricyclic spiroderivatives as modulators of chemokine receptor activity

Similar Documents

Publication Publication Date Title
JP2007509141A5 (enExample)
CA2326324C (en) Nitrogen-containing heterocyclic compound
JP6251183B2 (ja) 置換された縮合ピリミジンおよびトリアジン化合物ならびにその使用
DE60221392T2 (de) Neue pyrrolderivate als pharmazeutische mittel
JP2020519589A5 (enExample)
JP5097696B2 (ja) Vr1拮抗剤としての2,3−置換縮合ピリミジン−4(3h)−オン
JP2009528389A (ja) A2aアデノシン受容体拮抗剤
CA2809911A1 (en) Bicyclic aza heterocycles, and use thereof
NO328723B1 (no) Fremgangsmate for fremstilling av benzimidazol-2-yl kinolinonderivater
JP2002539126A (ja) チロシンキナーゼ阻害剤
US8022085B2 (en) Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof
AU2015320142B2 (en) Novel imidazopyridazine compounds and their use
CN103096718A (zh) 可溶性鸟苷酸环化酶活化剂
JPWO2005095419A1 (ja) チアゾロピリミジン誘導体
WO2008043745A1 (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
MX2012005827A (es) Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
JP2013520407A5 (enExample)
JP2006520397A (ja) 新規融合トリアゾロン類及びその使用
JP5487100B2 (ja) アデノシンa3受容体リガンドとしてのトリアゾロ[1,5−a]キノリン
JP2011042653A (ja) アデノシン受容体リガンドとして有用なトリアゾロ−キノリン誘導体
ES2406737T3 (es) Derivados de pirazol con actividad de tirosina quinasa
JP6339564B2 (ja) 抗マラリア剤としてのピリミジノン誘導体
CA2784013A1 (en) 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4, 3-c] isoquinoline derivatives
JP4409935B2 (ja) アミノキノリンおよびアミノピリジン誘導体およびそのアデノシンa3リガンドとしての使用
JP2007509866A (ja) チエノピリミジン